Insider Selling: Haemonetics Co. (NYSE:HAE) Insider Sells 1,084 Shares of Stock

Haemonetics Co. (NYSE:HAEGet Rating) insider Stewart W. Strong sold 1,084 shares of Haemonetics stock in a transaction that occurred on Thursday, May 19th. The shares were sold at an average price of $59.10, for a total value of $64,064.40. Following the sale, the insider now directly owns 15,756 shares in the company, valued at $931,179.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

NYSE HAE traded up $1.91 during mid-day trading on Monday, reaching $61.23. The stock had a trading volume of 497,412 shares, compared to its average volume of 561,421. Haemonetics Co. has a 1 year low of $43.50 and a 1 year high of $75.34. The stock has a market cap of $3.13 billion, a PE ratio of 72.89, a price-to-earnings-growth ratio of 2.21 and a beta of 0.44. The company has a fifty day moving average price of $56.58 and a 200 day moving average price of $55.05. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.71 and a quick ratio of 1.05.

Haemonetics (NYSE:HAEGet Rating) last posted its earnings results on Tuesday, May 10th. The medical instruments supplier reported $0.65 EPS for the quarter, topping analysts’ consensus estimates of $0.60 by $0.05. Haemonetics had a net margin of 4.37% and a return on equity of 18.57%. The business had revenue of $265.00 million during the quarter, compared to the consensus estimate of $257.11 million. During the same quarter in the previous year, the firm posted $0.46 EPS. The firm’s revenue was up 17.8% on a year-over-year basis. As a group, equities research analysts expect that Haemonetics Co. will post 2.72 earnings per share for the current year.

Several analysts have weighed in on HAE shares. Raymond James cut their price objective on Haemonetics from $70.00 to $66.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 9th. Needham & Company LLC cut Haemonetics from a “buy” rating to a “hold” rating in a research report on Thursday, January 27th. StockNews.com began coverage on shares of Haemonetics in a report on Thursday, March 31st. They set a “hold” rating for the company. Finally, Barrington Research lifted their target price on shares of Haemonetics from $71.00 to $77.00 in a report on Wednesday, May 11th. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, Haemonetics has an average rating of “Hold” and a consensus target price of $70.75.

Large investors have recently bought and sold shares of the business. Wellington Management Group LLP boosted its holdings in Haemonetics by 21.5% in the 1st quarter. Wellington Management Group LLP now owns 6,165,363 shares of the medical instruments supplier’s stock worth $389,776,000 after buying an additional 1,091,484 shares during the period. Capital Research Global Investors lifted its stake in Haemonetics by 166.1% in the 1st quarter. Capital Research Global Investors now owns 5,452,006 shares of the medical instruments supplier’s stock worth $344,676,000 after purchasing an additional 3,402,873 shares in the last quarter. Vanguard Group Inc. lifted its stake in Haemonetics by 0.6% in the 1st quarter. Vanguard Group Inc. now owns 4,909,896 shares of the medical instruments supplier’s stock worth $310,404,000 after purchasing an additional 28,960 shares in the last quarter. Neuberger Berman Group LLC raised its position in shares of Haemonetics by 2.6% during the 3rd quarter. Neuberger Berman Group LLC now owns 3,856,498 shares of the medical instruments supplier’s stock valued at $269,677,000 after buying an additional 96,188 shares in the last quarter. Finally, State Street Corp raised its position in shares of Haemonetics by 1.8% during the 4th quarter. State Street Corp now owns 1,691,193 shares of the medical instruments supplier’s stock valued at $89,701,000 after buying an additional 29,958 shares in the last quarter. 98.51% of the stock is owned by institutional investors and hedge funds.

Haemonetics Company Profile (Get Rating)

Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

Recommended Stories

Insider Buying and Selling by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.